The University of Chicago Header Logo

Connection

Rudolph Navari to Vomiting

Back to Details
This is a "connection" page, showing publications Rudolph Navari has written about Vomiting.
Rudolph Navari
Connection Strength
19.595
Vomiting
  1. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis. Future Oncol. 2021 Aug; 17(23):3027-3035.
    View in: PubMed
    Score: 0.669
  2. Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies. Future Oncol. 2020 Aug; 16(24):1863-1872.
    View in: PubMed
    Score: 0.631
  3. Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial. JAMA Oncol. 2020 06 01; 6(6):895-899.
    View in: PubMed
    Score: 0.629
  4. What the HEC? Clinician Adherence to Evidence-Based Antiemetic Prophylaxis for Highly Emetogenic Chemotherapy. J Natl Compr Canc Netw. 2020 06; 18(6):676-681.
    View in: PubMed
    Score: 0.629
  5. Nausea and Vomiting in Advanced Cancer. Curr Treat Options Oncol. 2020 02 05; 21(2):14.
    View in: PubMed
    Score: 0.615
  6. HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis. Future Oncol. 2019 Jan; 15(3):241-255.
    View in: PubMed
    Score: 0.561
  7. Safety of Polysorbate 80 in the Oncology Setting. Adv Ther. 2018 Jun; 35(6):754-767.
    View in: PubMed
    Score: 0.546
  8. Managing Nausea and Vomiting in Patients With Cancer: What Works. Oncology (Williston Park). 2018 03 15; 32(3):121-5, 131, 136.
    View in: PubMed
    Score: 0.539
  9. Olanzapine for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 10 06; 375(14):1396.
    View in: PubMed
    Score: 0.488
  10. Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomiting. Drugs Today (Barc). 2016 Aug; 52(8):431-438.
    View in: PubMed
    Score: 0.482
  11. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Jul 14; 375(2):134-42.
    View in: PubMed
    Score: 0.481
  12. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Apr 07; 374(14):1356-67.
    View in: PubMed
    Score: 0.472
  13. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Drug Saf. 2016; 15(3):343-56.
    View in: PubMed
    Score: 0.464
  14. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2015; 15(10):1127-33.
    View in: PubMed
    Score: 0.454
  15. Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting. Biomed Res Int. 2015; 2015:595894.
    View in: PubMed
    Score: 0.453
  16. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015 Sep; 16(9):1079-1089.
    View in: PubMed
    Score: 0.451
  17. 5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochim Biophys Acta. 2015 Oct; 1848(10 Pt B):2738-46.
    View in: PubMed
    Score: 0.439
  18. Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther. 2015; 9:155-61.
    View in: PubMed
    Score: 0.431
  19. Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2014 Jan 05; 722:180-6.
    View in: PubMed
    Score: 0.398
  20. The current status of the use of palonosetron. Expert Opin Pharmacother. 2013 Jul; 14(10):1281-4.
    View in: PubMed
    Score: 0.385
  21. Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents. Drugs. 2013 Mar; 73(3):249-62.
    View in: PubMed
    Score: 0.380
  22. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013 Jun; 21(6):1655-63.
    View in: PubMed
    Score: 0.377
  23. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011 Sep-Oct; 9(5):188-95.
    View in: PubMed
    Score: 0.344
  24. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol. 2010 Jul; 6(7):1073-84.
    View in: PubMed
    Score: 0.316
  25. Antiemetic control: toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother. 2009 Mar; 10(4):629-44.
    View in: PubMed
    Score: 0.288
  26. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs. 2009; 69(5):515-33.
    View in: PubMed
    Score: 0.285
  27. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2008 Nov; 8(11):1733-42.
    View in: PubMed
    Score: 0.282
  28. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities. Curr Opin Investig Drugs. 2008 Jul; 9(7):774-85.
    View in: PubMed
    Score: 0.275
  29. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs. 2007 Dec; 16(12):1977-85.
    View in: PubMed
    Score: 0.264
  30. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer. 2007 Nov; 15(11):1285.
    View in: PubMed
    Score: 0.252
  31. Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Canc Netw. 2007 Jan; 5(1):51-9.
    View in: PubMed
    Score: 0.248
  32. New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct; 12(5):341-7.
    View in: PubMed
    Score: 0.242
  33. Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar; 11(1):137-51.
    View in: PubMed
    Score: 0.234
  34. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer. 2005 Jul; 13(7):529-34.
    View in: PubMed
    Score: 0.218
  35. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2004 Oct; 4(5):715-24.
    View in: PubMed
    Score: 0.212
  36. Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials. Cancer Invest. 2004; 22(4):569-76.
    View in: PubMed
    Score: 0.202
  37. Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602). Oncologist. 2023 08 03; 28(8):722-729.
    View in: PubMed
    Score: 0.196
  38. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents. J Support Oncol. 2003 Jul-Aug; 1(2):89-103.
    View in: PubMed
    Score: 0.195
  39. Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy. Adv Ther. 2023 07; 40(7):3217-3226.
    View in: PubMed
    Score: 0.193
  40. Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles. Oncologist. 2023 03 17; 28(3):208-213.
    View in: PubMed
    Score: 0.191
  41. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021 Jul; 29(7):3439-3459.
    View in: PubMed
    Score: 0.164
  42. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients. Support Care Cancer. 2021 Aug; 29(8):4269-4275.
    View in: PubMed
    Score: 0.164
  43. Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin. Oncologist. 2021 04; 26(4):325-331.
    View in: PubMed
    Score: 0.163
  44. The Importance of a Cause-Based Protocol to Approach Cancer-Related Nausea and Vomiting-Reply. JAMA Oncol. 2020 11 01; 6(11):1812-1813.
    View in: PubMed
    Score: 0.162
  45. Olanzapine is an effective antiemetic agent. Ann Palliat Med. 2020 05; 9(3):628-630.
    View in: PubMed
    Score: 0.156
  46. Impact of Addition of Carboplatin AUC = 4 to Antiemetic Guidelines for Triple Antiemetic Prophylaxis: A Gap in Quality of Care, Guideline Adoption, and Avoiding Acute Care. JCO Oncol Pract. 2020 02; 16(2):e132-e138.
    View in: PubMed
    Score: 0.152
  47. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Expert Opin Drug Saf. 2020 Feb; 19(2):205-210.
    View in: PubMed
    Score: 0.151
  48. The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy. Expert Opin Drug Saf. 2019 Dec; 18(12):1127-1132.
    View in: PubMed
    Score: 0.151
  49. Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis. Crit Rev Oncol Hematol. 2019 Oct; 142:164-186.
    View in: PubMed
    Score: 0.148
  50. Use of placebos in delayed-emesis studies. J Clin Oncol. 1999 May; 17(5):1648-50.
    View in: PubMed
    Score: 0.146
  51. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med. 1999 Jan 21; 340(3):190-5.
    View in: PubMed
    Score: 0.143
  52. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol. 2018 07 01; 29(7):1535-1540.
    View in: PubMed
    Score: 0.138
  53. Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer. 2018 Aug; 26(8):2519-2549.
    View in: PubMed
    Score: 0.137
  54. Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients. Paediatr Drugs. 2017 Jun; 19(3):213-222.
    View in: PubMed
    Score: 0.128
  55. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2017 01; 25(1):303-308.
    View in: PubMed
    Score: 0.123
  56. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. Support Care Cancer. 2017 01; 25(1):85-92.
    View in: PubMed
    Score: 0.121
  57. 2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. Support Care Cancer. 2017 01; 25(1):277-288.
    View in: PubMed
    Score: 0.120
  58. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer. 2016 Apr; 57:23-30.
    View in: PubMed
    Score: 0.117
  59. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis. Support Care Cancer. 2016 May; 24(5):2381-2392.
    View in: PubMed
    Score: 0.116
  60. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review. Support Care Cancer. 2016 Feb; 24(2):1001-1008.
    View in: PubMed
    Score: 0.114
  61. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol. 1995 Sep; 13(9):2408-16.
    View in: PubMed
    Score: 0.113
  62. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol. 2015 Sep; 16(9):1071-1078.
    View in: PubMed
    Score: 0.113
  63. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol. 1995 May; 13(5):1242-8.
    View in: PubMed
    Score: 0.111
  64. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2014 Dec; 15(17):2599-608.
    View in: PubMed
    Score: 0.106
  65. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol. 1994 Oct; 12(10):2204-10.
    View in: PubMed
    Score: 0.106
  66. Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol. 2014 Mar; 12(3 Suppl 9):1-14; quiz 15.
    View in: PubMed
    Score: 0.102
  67. Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist. Expert Opin Drug Metab Toxicol. 2009 Dec; 5(12):1577-86.
    View in: PubMed
    Score: 0.076
  68. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest. 2004; 22(3):383-8.
    View in: PubMed
    Score: 0.050
  69. 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2023 Dec 18; 32(1):36.
    View in: PubMed
    Score: 0.050
  70. Work loss and activity impairment due to extended nausea and vomiting in patients with breast cancer receiving CINV prophylaxis. Support Care Cancer. 2023 Oct 25; 31(12):654.
    View in: PubMed
    Score: 0.050
  71. Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Cancer Med. 2023 08; 12(15):15769-15776.
    View in: PubMed
    Score: 0.049
  72. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer. 2002 Jun 01; 94(11):3032-41.
    View in: PubMed
    Score: 0.045
  73. Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis. Support Care Cancer. 2022 Feb; 30(2):1015-1018.
    View in: PubMed
    Score: 0.044
  74. Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies. Crit Rev Oncol Hematol. 2021 Jan; 157:103143.
    View in: PubMed
    Score: 0.041
  75. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. Oncologist. 2020 03; 25(3):e589-e597.
    View in: PubMed
    Score: 0.038
  76. Thalidomide: Rebirth of a Gestational Antiemetic? J Clin Oncol. 2017 11 01; 35(31):3523-3524.
    View in: PubMed
    Score: 0.033
  77. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations. Drug Des Devel Ther. 2017; 11:2621-2629.
    View in: PubMed
    Score: 0.033
  78. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol. 1997 Aug; 15(8):2966-73.
    View in: PubMed
    Score: 0.032
  79. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. J Clin Oncol. 1997 May; 15(5):2135-8.
    View in: PubMed
    Score: 0.032
  80. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol. 1997 Feb; 8(2):181-5.
    View in: PubMed
    Score: 0.031
  81. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer. 1997 Jan; 5(1):31-7.
    View in: PubMed
    Score: 0.031
  82. Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group. Cancer Invest. 1997; 15(4):297-303.
    View in: PubMed
    Score: 0.031
  83. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol. 1996 Aug; 14(8):2242-9.
    View in: PubMed
    Score: 0.030
  84. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1992 Dec; 10(12):1969-75.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.